ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Abatacept"

  • Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting

    Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial

    Kensuke Kume1, Kanzo Amano1, Susumu Yamada1, Kazuhiko Hatta2, Kuniki Amano3, Noriko Kuwaba4 and Hiroyuki Ohta5, 1Rheumatology, Hiroshima Clinic, Hiroshima, Japan, 2Rheumatology, Hatta Clinic, Kure, Japan, 3Rheumatology, Sky Clinic, Hiroshima, Japan, 4Medical Research, Sanki Clinical Link, Hiroshima, Japan, 5Medical Research, hiroshima clinic, Hiroshima, Japan

    Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…
  • Abstract Number: 2465 • 2012 ACR/ARHP Annual Meeting

    Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 2011–2012 Flu Season

    Masatoshi Hayashi1, Toshihisa Kojima2, Naoki Ishiguro3, Tomonori Kobayakawa4 and Toshihisa Kanamono1, 1Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, 2Orthopedic Surgery and Rheumatology, Nagoya Univeristy, School of Medicine, Nagoya, Japan, 3Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 4Orthopedic Surgery, Nagoya university, Nagoya, Japan

    Background/Purpose: At present, annual vaccination against influenza is recommended for rheumatoid arthritis (RA) patients. However, whether humoral responses to influenza vaccine are impaired in RA…
  • Abstract Number: 350 • 2012 ACR/ARHP Annual Meeting

    Reduction of Inflammation with Abatacept and Tocilizumab Results in Lower N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From Prospective Cohort Studies

    Inge A.M. van den Oever and Mike T. Nurmohamed, Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of heart failure (HF). The chronic inflammatory state in RA is associated with increased levels of…
  • Abstract Number: 2163 • 2012 ACR/ARHP Annual Meeting

    Abatacept Monotherapy Effectively Reduces the Frequency of Osteoclast Precursor Cells in the Peripheral Blood of Patients with Rheumatoid Arthritis and Inhibits Their Differentiation Into Osteoclasts

    Sandra Mueller-Schmucker1, Roland Axmann1, Sonja Herman2, Mario Zaiss1, Manuela Le Bars3, Thomas Harrer1 and Georg A. Schett4, 1University of Erlangen-Nuremberg, Erlangen, Germany, 2Rheumatology, Medical University of Vienna, Vienna, Austria, 3Bristol-Myers Squibb, Rueil Malmaison, France, 4Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Bone resorbing osteoclasts origin from monocytes. We have recently shown that binding of abatacept (CTLA4-Ig) to CD80 and CD86 on the surface of monocytes…
  • Abstract Number: 289 • 2012 ACR/ARHP Annual Meeting

    Mycophenolate Mofetil and Abatacept Combination Therapy in Refractory Pediatric Systemic Lupus Erythematosus Nephritis

    Rhina Castillo1, Suhas M. Radhakrishna2, Andreas O. Reiff3 and Katherine AB Marzan1, 1Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, 2Pediatric Rheumatology, Kaiser Permananete Medical Group, Oakland, CA, 3Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA

    Background/Purpose: Nephritis (LN) in pediatric systemic lupus erythematosus (pSLE) requires treatment (tx) with corticosteroids (CS) and other agents such as mycophenolate mofetil (MMF) or cyclophosphamide…
  • Abstract Number: 1923 • 2012 ACR/ARHP Annual Meeting

    Biologics in Relapsing Polychondritis: A Single Center Case-Series

    Guillaume Moulis1, Laurent Sailler2, Grégory Pugnet3, Leonardo Astudillo2 and Philippe Arlet1, 1Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, Toulouse, France, 2Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, 3Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France

    Background/Purpose: First-line treatment for relapsing polychondritis (RP) is costicosteroids (CS). Dapsone and methotrexate have been proposed as second-line therapies. Only few reports have been published…
  • Abstract Number: 275 • 2012 ACR/ARHP Annual Meeting

    Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results

    Anjali Patwardhan1, Kelly A. Rouster-Stevens2, Harry L. Gewanter3, Grant D. Syverson4, Renee F. Modica5, Kara M. Schmidt6 and Charles H. Spencer7, 1Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 2Pediatric Rheumatologist, Emory-Children's Center, Atlanta,, GA, 3Pediatric & Adolescent HP, Pediatric & Adolescent HP, Midlothian, VA, 4Pediatric Rheumatology, Medical College of Wisconsin, Wauwatosa, WI, 5Pediatric Rheumatology, University of Florida, Gainesville, FL, 6Pediatric Rheumatology, Univ of Louisville, Louisville, KY, 7Rheumatology, Nationwide Childrens Hospital, Columbus, OH

    Background/Purpose: Biologic therapy is increasingly prescribed in rheumatologic disorders.  Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in…
  • Abstract Number: 1679 • 2012 ACR/ARHP Annual Meeting

    Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up

    D. J. Lovell1, N. Ruperto2, R. Mouy2, E. Paz2, N. Rubio-Perez2, C. A. Silva2, C. Abud-Mendoza2, R. Burgos-Vargas2, V. Gerloni2, J. a. Melo-Gomes3, C. Saad-Magalhaes2, J. Chavez4, C. Huemer2, A. Kivitz2, F. Blanco2, I. Foeldvari2, Michael Hofer5, H. Huppertz2, C. Job Deslandre2, K. Minden2, A. Flores Nunez6, A. J. Block7 and A. Martini2, 1Cincinnati Children's Hospital, Cincinnati, OH, 2PRINTO, IRCCS G. Gaslini, Genoa, Italy, 3Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, 4PRINTO, Genoa, Italy, 5Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, 6PRINTO, IRCCS Hospital para el Niño Poblano, Puebla, Mexico, 7Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: We previously reported the efficacy and safety of abatacept (ABA) in patients with juvenile idiopathic arthritis (JIA) in the AWAKEN trial1, during the 4-month…
  • Abstract Number: 5 • 2012 ACR/ARHP Annual Meeting

    Adalimumab Inhibits TNF-Enhanced Human Osteoclast Development More Effectively Than Other Biologic Agents Under in Vitro Conditions of Chronic TNF Exposure

    Bohdan P. Harvey1 and Zehra Kaymakcalan2, 1Biologics, Abbott Laboratories, Worcester, MA, 2Biologics, Abbott, Worcester, MA

    Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …
  • Abstract Number: 1695 • 2012 ACR/ARHP Annual Meeting

    Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data

    M. C. Genovese1, M C. Hochberg2, R. B. Cohen3, M. E. Weinblatt4, J. Kaine5, Edward Keystone6, P. Nash7, I. Delaet8 and R. Alten9, 1Stanford University, Palo Alto, CA, 2Department of Medicine, University of Maryland, Baltimore, MD, 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 4Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 5Sarasota Arthritis Research Center, Sarasota, FL, 6Mount Sinai Hospital, Toronto, ON, Canada, 7University of Queensland, Brisbane, Australia, 8Bristol-Myers Squibb, Princeton, NJ and Bristol-Myers Squibb, Hopewell, VA, 9Schlosspark-Klinik, University Medicine, Berlin, Germany

    Background/Purpose: Disease-modifying therapies for RA have proven efficacy, but these drugs may have selective toxicities, such as malignancy, that may increase with duration of treatment.…
  • Abstract Number: 1655 • 2012 ACR/ARHP Annual Meeting

    An Open-Label Trial of Abatacept in Mild Relapsing Granulomatosis with Polyangiitis (Wegener’s)

    Carol A. Langford1, David Cuthbertson2, Gary S. Hoffman3, Jeffrey Krischer4, Carol McAlear5, Paul A. Monach6, Philip Seo7, Ulrich Specks8, Steven R. Ytterberg9, Peter A. Merkel5 and for the Vasculitis Clinical Research Consortium5, 1Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 2Department of Biostatistics, University of South Florida, Tampa, FL, 3Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, 4University of South Florida, Tampa, FL, 5University of Pennsylvania, Philadelphia, PA, 6Rheumatology, Boston University, Boston, MA, 7Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 8Mayo Clinic, Rochester, MN, 9Rheumatology Division, Mayo Clinic, Rochester, MN

    Background/Purpose: Granulomatosis with polyangiitis (Wegener's, GPA) is a primary systemic vasculitis that carries a high predilection for relapse. An area of unmet need has been…
  • Abstract Number: 1340 • 2012 ACR/ARHP Annual Meeting

    Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial

    Roy Fleischmann1, Michael H. Schiff2, Michael E. Weinblatt3, Michael A. Maldonado4, Elena M. Massarotti5 and Yusuf Yazici6, 1Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, 2Rheumatology Division, University of Colorado, Denver, CO, 3Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 4Medical Strategy, Bristol-Myers Squibb, Princeton, NJ, 5Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6New York University, New York, NY

    Background/Purpose: Advancements in the understanding of Rheumatoid Arthritis (RA) have led to the development of novel therapeutics and treatment guidelines that target remission as an…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology